Cardio Diagnostics (CDIO) Stock Price, News & Analysis

Company Overview

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $4.05 to $4.42
• 50-Day Range: $3.84 to $15.60
• 52-Week Range: $3.40 to $53.10
• Volume: 40,572 shs
• Average Volume: 91,422 shs
• Market Capitalization: $7.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.00
• Consensus Rating: Buy

Cardio Diagnostics Stock Analysis - MarketRank™

Cardio Diagnostics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cardio Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cardio Diagnostics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Cardio Diagnostics has a P/B Ratio of 30.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.48% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 95.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardio Diagnostics does not currently pay a dividend.

Dividend Growth

Cardio Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.48% of the float of Cardio Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Cardio Diagnostics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cardio Diagnostics has recently decreased by 95.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.48

News Sentiment

Cardio Diagnostics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Cardio Diagnostics this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for CDIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added Cardio Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardio Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.30% of the stock of Cardio Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.06% of the stock of Cardio Diagnostics is held by institutions.

CDIO Stock Analysis - Frequently Asked Questions

How have CDIO shares performed this year?

Cardio Diagnostics' stock was trading at $27.51 at the start of the year. Since then, CDIO shares have decreased by 84.7% and is now trading at $4.21.
View the best growth stocks for 2025 here.

How were Cardio Diagnostics' earnings last quarter?

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) posted its quarterly earnings data on Thursday, May, 15th. The company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.91. The company had revenue of $0 million for the quarter, compared to analyst estimates of $0.05 million. Cardio Diagnostics had a negative trailing twelve-month return on equity of 258.85% and a negative net margin of 22,732.03%.

When did Cardio Diagnostics' stock split?

Cardio Diagnostics shares reverse split before market open on Tuesday, May 13th 2025. The 1-30 reverse split was announced on Thursday, May 8th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Cardio Diagnostics' major shareholders?

Top institutional investors of Cardio Diagnostics include Jane Street Group LLC (4.66%). Insiders that own company stock include Robert Philibert and Meeshanthini Dogan.
View institutional ownership trends.

How do I buy shares of Cardio Diagnostics?

Shares of CDIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cardio Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardio Diagnostics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), MSP Recovery (LIFW), MSP Recovery (LIFW), NuCana (NCNA), Recursion Pharmaceuticals (RXRX) and SoundHound AI (SOUN).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 5/29/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDIO
• CIK: 1870144
• Web: cardiodiagnosticsinc.com
• Phone: 302-281-2147
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $60.00
• High Stock Price Target: $60.00
• Low Stock Price Target: $60.00
• Potential Upside/Downside: +1,325.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.38 million
• Net Margins: -22,732.03%
• Pretax Margin: -22,732.03%
• Return on Equity: -258.85%
• Return on Assets: -191.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.50
• Quick Ratio: 8.50

Sales & Book Value

• Annual Sales: $19,902.00
• Price / Sales: 367.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.14 per share
• Price / Book: 30.07

Miscellaneous

• Outstanding Shares: 1,739,000
• Free Float: 40,517,000
• Market Cap: $7.32 million
• Optionable: Not Optionable
• Beta: 3.70